This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
Context. “Compound 57” (Roche) is an oral allosteric EGFRL858R inhibitor being developed for NSCLC. Drug resistance and associated disease relapse…
molecule
10 months ago ●
5 mins read
The FDA recently approved Agios' Pyrukynd (mitapivat, AG-348), a first-in-class, allosteric activator of pyruvate kinase (PK), for treatment of hemolytic…
Article
2 years ago ●
3 mins read
Context. AN15368 (Anacor Pharmaceuticals) is an oral Cleavage And Polyadenylation Specificity Factor (CPSF3) inhibitor being developed for Chagas disease, also…
molecule
10 months ago ●
5 mins read
together with Dr. Jennifer Huen, Saumil Patel, and Dr. Naveed Yasin In 2021, the FDA approved 9 non-radiological novel small…
Article
2 years ago ●
18 mins read
Context. UCB7362(UCB Biopharma) is an oral plasmepsin X (PMX) inhibitor being developed as an antimalarial agent. Malaria is a protozoan…
molecule
10 months ago ●
5 mins read
with Dr. Romyr Dominique Contrary to popular belief, pharma is incredibly competitive, with dozens of companies often working on the…
Article
2 years ago ●
4 mins read
Load More
